

## News Release

**August 5, 2016**

**Carna Biosciences, Inc.**

**Kohichiro Yoshino, President & CEO**

**(Code:4572, Jasdaq Glowth)**

<http://www.carnabio.com/english/>

### **Carna Biosciences Announces Termination of Collaboration with Johnson & Johnson Innovation**

Carna Bioscience announced today that Janssen Biotech, Inc. is terminating the license agreement for one of Carna Bioscience's small molecule protein kinase inhibitors for strategic reasons.

Carna Bioscience had granted to Janssen an exclusive, worldwide license for the development and commercialization of the molecule in June, 2015. Upon termination of the agreement effective August 23<sup>rd</sup>, 2016, Janssen Biotech, Inc. will return all rights to develop and commercialize the molecule to Carna Bioscience.

Carna Bioscience believes that the molecule remains promising and is actively seeking a new partner to develop and commercialize the molecule.

The termination of the agreement will not materially affect Carna Biosciences's 2016 financial results.